Navigation Links
Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Date:2/6/2008

EMERYVILLE, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the BIO CEO & Investor Conference on Wednesday, February 13, at 11:00 a.m. Eastern Time. Interested parties may access a live webcast of the presentation at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ONXX&item_id=17524 28

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to listen to the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through March 13, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other tumor types. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
2. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
3. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
8. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Anthera Pharmaceuticals Forms Scientific Advisory Board
11. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013   Oligomerix, Inc. , a ... modifying therapeutics for Alzheimer,s disease (AD) and related ... Series B financing, which includes both issuance of ... represent approximately $2.8M in new investments in the ... the raise. Funding from the ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 /PRNewswire/ ... regenerative medicine, presented new data generated in collaboration with ... leading health economics consultancy) demonstrating the significant healthcare resource ... venous leg ulcers (VLU) place upon the US healthcare ... which reveal annual costs of up to $15 billion ...
(Date:5/22/2013)... May 22, 2013 AudioNotch ... therapy for tinnitus treatment. AudioNotch is pleased to ... With clinic locations in both British Columbia and ... audiology and hearing services. AudioNotch's tinnitus treatment program ... Upon entering a Destination Hearing clinic, patients have ...
(Date:5/22/2013)... Alton Housing Authority was hit by bed ... that their presence has already caused the company $35,000 ... such big spending, My Cleaning Products shared a way ... said in the report that to clear the infestation ... that, its employees also attended a mandatory training on bed ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2
... ) today announced the Webcast of its fourth quarter and year-end 2008 ... on Tuesday, February 10, and will include remarks by Peer M. Schatz, ... What: Webcast of QIAGEN,s fourth quarter ... results call, When: ...
... Commence Tender Offer for All Shares of Common StockAt ... Feb. 3 PharmaNet Development Group, Inc. (the "Company" ... provider of clinical development services, today announced that it ... affiliates of JLL Partners, Inc. ("JLL"). Under the terms ...
... Therapeutic Approach Provides HIV-Resistant Immune CellsRICHMOND, Calif., Feb. 3 ... announced today that its collaborators at the University ... trial to evaluate SB-728-T for the treatment of HIV/AIDS. ... technology, SB-728-T has been shown in an animal ...
Cached Biology Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 3PharmaNet Development Group Agrees to be Acquired by JLL Partners 4PharmaNet Development Group Agrees to be Acquired by JLL Partners 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 6PharmaNet Development Group Agrees to be Acquired by JLL Partners 7Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 2Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 3Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 4Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 5Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 6Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 7
(Date:5/22/2013)... feared Legionella pneumophila bacteria is responsible for ... In order to infect us, this pathogen has developed ... go unnoticed in our cells, thus avoiding these acting ... Basque biosciences research centre, CIC bioGUNE, in which teams ... USA and the National Supercomputation Centre in Barcelona (BSC) ...
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
(Date:5/21/2013)... A new analysis shows that the nation,s land ... enough algae to produce up to 25 billion gallons ... one-twelfth of the country,s yearly needs. , The findings ... that would be needed to grow significant amounts of ... were published in the May 7 issue of ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4
... burned your finger on a hot stove? Imagine what it's ... feet all the time and know there's virtually nothing you ... it's a common complication of many diseases and medical conditions, ... pain, which is caused by damage to sensory neurons that ...
... biochemists reveal the first structural details of a family ... present in a variety of bacteria. The discovery was ... is the first look at how microcompartments are built, ... Yeates, UCLA professor of chemistry and biochemistry, and a ...
... The recent discovery of citrus greening (huanglongbing) in samples ... threat to Florida's $9 billion commercial citrus industry. Proper ... amount of crop loss caused by this disease, say ... greening is a bacterial disease that affects the phloem ...
Cached Biology News:Scientists use gene transfer technology and common virus to block neuropathic pain 2Scientists use gene transfer technology and common virus to block neuropathic pain 3Scientists use gene transfer technology and common virus to block neuropathic pain 4Nighttime Dying Linked To Sleep Apnea From Brain Cell Loss 2Nighttime Dying Linked To Sleep Apnea From Brain Cell Loss 3
... DNA Ladder is suitable for ... to 16 kb by agarose ... can be visualized by ethidium ... be detected on Southern blots ...
...
... Hormone Receptor 2 ( Abpromise ... Antigen: Synthetic peptide: AFRHCNPNGTWDFMHSLN, ... of Human Parathyroid Hormone Receptor 2 ... 5746 Swiss ...
... 5 ml Dynabeads Mouse pan ... anti-B220 monoclonal antibody. For the efficient ... B cells directly from spleen or ... is expressed on mouse B cells ...
Biology Products: